We are resourced with the region’s only single cell sequencing facility that couples single cell capture with next generation sequencing technologies.
Research includes investigation of tumour predisposition syndromes as a model to discover oncogenic dependencies and deliver interventional clinical trials for patient benefit. A landmark study reflecting this is CAPP3 where aspirin has been highlighted as a chemoprevention strategy in families with colorectal cancer predisposition due to mutations in DNA mismatch repair genes. Bioinformatic analysis of data from rare cancers has also led to the development of novel diagnostic tests in mismatch repair. Other research investigates cancer stem cells, kidney cancer, RNA splicing biology controls in prostate and breast cancer, the functions of microRNAs in breast cancer, and the biology of sugar modifications of both protein and lipids in prostate cancer. Clinical outputs from these research areas are instrumental to gain novel insights for prognostic and therapeutic benefit for patients. We have also have an active rare genetic disease group that partners with rare disease patients to carry out first in human interventions based on transcriptomic profiling of skin tumours, as well as a rare disease public engagement programme.
Researchers and SpecialismsResearchers and Specialisms
John Burn: CAPP trial, colorectal cancer
David Elliott: RNA splicing regulation, breast cancer, prostate cancer
Mike Jackson: genomic instability and somatic variation
David Llobet-Navas:microRNAs, breast cancer, endometrial cancer , autophagy
Annette Meeson: cancer stem cells, breast cancer, ovarian cancer, thyroid cancer, hypoxia, EMT, multidrug resistance, transporters
Colin Miles: Wilms Tumour, WT1 gene and Leukaemia
Jennifer Munkley: prostate cancer, glycosylation patterns, androgen receptor
Neil Rajan: CYLD, Tumour transcriptomics, TRK, Clinical trials
Ruth Rodriguez-Barrueco: Glycosylation, breast cancer, siRNA screens
Mauro Santibanez-Koref: allelic expression and cancer